Back to News
Market Impact: 0.35
Novartis' Pelacarsen Fails To Meet Primary Endpoint In Phase III Lp(a)HORIZON Trial
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsAnalyst InsightsTechnology & Innovation
Novartis said its phase III Lp(a)HORIZON trial of pelacarsen failed to meet the primary endpoint. The negative trial outcome raises significant risk around pelacarsen’s clinical and commercial outlook. Expect potential knock-on pressure for NVS sentiment as investors reassess pipeline value and development prospects.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
NVS-0.80
More News
- 'Cannot play hide and seek': Singapore minister's warning over haze sends agricultural stocks lower
- BlackRock, GIC among investors chasing Indian telecom major Jio's IPO as anchor bids top $26 billion
- Nscale, Anthropic Eye $45 Billion Cloud Deal as AI Trade Rebounds
- Volkswagen bet on Xpeng to save its China business. It’s not going to plan
- Gartner analyst behind tech rout: AI returns are not yet large enough to justify neocloud build-out
- Elice shares plunge 28% on debut as investor doubts over AI trade deepen